Is POLB or CIR more profitable?

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Circassia Group N/A N/A N/A

Is POLB or SCLP more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Scancell -116.98% 90.29% -45.28%

Is TILS or POLB more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Poolbeg Pharma N/A -55.47% -21.33%

Which has higher valuation & earnings, POLB or VSN?

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Poolbeg Pharma N/A N/A -£4.50B -£0.94 N/A Verseon N/A N/A N/A -£14.30 N/A

Is POLB or VSN more profitable?

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% Verseon N/A N/A N/A

Which has stronger earnings and valuation, MPH or POLB?

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group plc (MPH.L) N/A N/A N/A -£128.00 N/A Poolbeg Pharma N/A N/A -£4.50B -£0.94 N/A

Is MPH or POLB more profitable?

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group plc (MPH.L) N/A N/A N/A Poolbeg Pharma N/A -55.47% -21.33%

Poolbeg Pharma (POLB) Competitors

GBX 6.13 -0.03 (-0.49%)

As of 11:54 AM Eastern

Compare

POLB vs. CIR, SCLP, TILS, VSN, and MPH

Should you buy Poolbeg Pharma stock or one of its competitors? MarketBeat compares Poolbeg Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Poolbeg Pharma include Circassia Group (CIR), Scancell (SCLP), Tiziana Life Sciences (TILS), Verseon (VSN), and Mereo BioPharma Group plc (MPH.L) (MPH). These companies are all part of the "biotechnology" industry.

How does Poolbeg Pharma compare to Circassia Group?

Poolbeg Pharma (LON:POLB) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Circassia Group's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Circassia Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Poolbeg Pharma	Negative
Circassia Group	Neutral

Circassia Group has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

Circassia Group's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Circassia Group	N/A	N/A	N/A

Summary

Circassia Group beats Poolbeg Pharma on 6 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Scancell?

Poolbeg Pharma (LON:POLB) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Comparatively, 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Scancell has higher revenue and earnings than Poolbeg Pharma. Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Scancell	£4.71M	29.47	-£6.75M	-£0.55	N/A

Poolbeg Pharma has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Scancell	-116.98%	90.29%	-45.28%

Poolbeg Pharma has a beta of 1.812, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, Scancell has a beta of 0.736, suggesting that its stock price is 26% less volatile than the broader market.

In the previous week, Scancell had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Poolbeg Pharma. Scancell's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Scancell is being referred to more favorably in the news media.

Company	Overall Sentiment
Poolbeg Pharma	Negative
Scancell	Neutral

Summary

Scancell beats Poolbeg Pharma on 7 of the 12 factors compared between the two stocks.

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Poolbeg Pharma	N/A	-55.47%	-21.33%

1.5% of Poolbeg Pharma shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tiziana Life Sciences has higher earnings, but lower revenue than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
Poolbeg Pharma	Negative

Summary

Tiziana Life Sciences and Poolbeg Pharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Poolbeg Pharma compare to Verseon?

Poolbeg Pharma (LON:POLB) and Verseon (LON:VSN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

Verseon's return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
Verseon	N/A	N/A	N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Verseon's average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Verseon is being referred to more favorably in the news media.

Company	Overall Sentiment
Poolbeg Pharma	Negative
Verseon	Neutral

Summary

Verseon beats Poolbeg Pharma on 4 of the 7 factors compared between the two stocks.

How does Poolbeg Pharma compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A

1.5% of Poolbeg Pharma shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.95 indicating that Mereo BioPharma Group plc (MPH.L) is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group plc (MPH.L)	Neutral
Poolbeg Pharma	Negative

Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A
Poolbeg Pharma	N/A	-55.47%	-21.33%

Summary

Mereo BioPharma Group plc (MPH.L) beats Poolbeg Pharma on 4 of the 7 factors compared between the two stocks.

Get Poolbeg Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POLB vs. The Competition

Export

Metric	Poolbeg Pharma	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£43.22M	£515.16M	£6.81B	£2.79B
Dividend Yield	N/A	3.90%	2.67%	6.16%
P/E Ratio	-6.52	3.15	27.00	368.25
Price / Sales	N/A	6,249.84	517.85	84,392.87
Price / Cash	2.11	13.13	26.68	27.89
Price / Book	0.00	87.68	10.67	7.59
Net Income	-£4.50B	-£96.07M	£3.60B	£5.89B
7 Day Performance	1.32%	-0.59%	-0.37%	0.05%
1 Month Performance	-19.34%	1.23%	1.80%	-0.66%
1 Year Performance	104.33%	60.49%	25.50%	62.48%

Poolbeg Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POLB Poolbeg Pharma	N/A	GBX 6.13 -0.5%	N/A	+100.0%	£43.22M	N/A	N/A	12	Gap Up
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
SCLP Scancell	N/A	GBX 13 -4.4%	N/A	+32.0%	£134.91M	£4.71M	N/A	51	Gap Up
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:POLB) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Poolbeg Pharma (POLB) Competitors

POLB vs. CIR, SCLP, TILS, VSN, and MPH

How does Poolbeg Pharma compare to Circassia Group?

Summary

How does Poolbeg Pharma compare to Scancell?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Summary

How does Poolbeg Pharma compare to Verseon?

Summary

How does Poolbeg Pharma compare to Mereo BioPharma Group plc (MPH.L)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Poolbeg Pharma (POLB) Competitors

POLB vs. CIR, SCLP, TILS, VSN, and MPH

How does Poolbeg Pharma compare to Circassia Group?

Do institutionals and insiders hold more shares of POLB or CIR?

Does the media prefer POLB or CIR?

Which has higher valuation and earnings, POLB or CIR?

Is POLB or CIR more profitable?

Summary

How does Poolbeg Pharma compare to Scancell?

Do institutionals and insiders hold more shares of POLB or SCLP?

Which has higher valuation & earnings, POLB or SCLP?

Is POLB or SCLP more profitable?

Which has more risk and volatility, POLB or SCLP?

Does the media prefer POLB or SCLP?

Summary

How does Poolbeg Pharma compare to Tiziana Life Sciences?

Is TILS or POLB more profitable?

Do institutionals & insiders hold more shares of TILS or POLB?

Which has preferable earnings and valuation, TILS or POLB?

Does the media prefer TILS or POLB?

Summary

How does Poolbeg Pharma compare to Verseon?

Which has higher valuation & earnings, POLB or VSN?

Is POLB or VSN more profitable?

Do insiders & institutionals have more ownership in POLB or VSN?

Does the media prefer POLB or VSN?

Summary

How does Poolbeg Pharma compare to Mereo BioPharma Group plc (MPH.L)?

Which has stronger earnings and valuation, MPH or POLB?

Do institutionals and insiders believe in MPH or POLB?

Does the media favor MPH or POLB?

Is MPH or POLB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POLB vs. The Competition

Poolbeg Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools